Evidence map›Paper›PMID 41531940›Full record

ArticleClinical and translational radiation oncology2026

Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials.

Jingyi Shen, Dashan Ai, Yun Chen, Qi Liu, Jiaying Deng, Shengnan Hao, Xiaofei Zhang, Junhua Zhang, Yutong Zhang, Li Chu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jingyi ShenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Dashan AiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Qi LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jiaying DengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shengnan HaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaofei ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Junhua ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yutong ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Li ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yihua SunDivision of Thoracic Surgery, Department of Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yawei ZhangDivision of Thoracic Surgery, Department of Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jiaqing XiangDivision of Thoracic Surgery, Department of Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Longsheng MiaoDivision of Thoracic Surgery, Department of Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Haiquan ChenDivision of Thoracic Surgery, Department of Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hongcheng ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To explore efficacy and safety of postoperative chemoradiotherapy in esophageal squamous cell carcinoma. Materials and methods: Two single-arm, phase II trials (ESO-Shanghai 9 and 17) were conducted with the same inclusion criteria: 1) age 18-75, 2) ECOG 0-1, 3) within 3 months after surgery, 4) pathologically confirmed esophageal squamous cell carcinoma(pT3-4orN+,M0), with R0 margins, 5) no preoperative therapy. Both were postoperative concurrent chemoradiotherapy with weekly paclitaxel and carboplatin, and extended-field or small T-shaped field radiotherapy at dose of 45 Gy/25Fx or 50.4 Gy/28Fx in ESO-Shanghai 9 or 17. The primary endpoint was 2-year local control rate, secondary endpoints including overall survival, treatment-related toxicities, and failure patterns. Results: ESO-Shanghai 17 enrolled 70 patients from 2020 to 2023. 2-year local control rate was 83.8 %, and 1, 2, 3-year overall survival rates were 95.7 %, 84.0 %, 67.1 %. Local recurrence occurred in 24.3 % and distant metastasis in 21.4 %. There were no significant differences in local recurrence and metastasis. Both studies exhibited similar local recurrence-free survival and overall survival, disease free survival, and distant metastasis-free survival ( Conclusion: Postoperative chemoradiotherapy (50.4 Gy/28Fx with small T-shaped field) yielded local control and survival comparable to ESO-Shanghai 9, with no radiation pneumonitis-related deaths in esophageal squamous cell carcinoma.(

Indexed as

ChemotherapyCTVEsophageal squamous cell carcinomaPostoperative adjuvant therapyRadiotherapy

Identifiers

PMID41531940
PMCPMC12794425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.